Rzeszów University of Technology, Faculty of Chemistry, 6 Powstańców Warszawy Ave., 35-959 Rzeszów, Poland.
Department of Urology, John Paul II Hospital, Grunwaldzka 4 St., 36-100 Kolbuszowa, Poland.
J Pharm Biomed Anal. 2021 Jan 30;193:113752. doi: 10.1016/j.jpba.2020.113752. Epub 2020 Nov 6.
Kidney cancer is one of the most frequently diagnosed cancers of the urinary tract in the world. Despite significant advances in kidney cancer treatment, no urine specific biomarker is currently used to guide therapeutic interventions. In an effort to address this knowledge gap, metabolic profiling of urine samples from 50 patients with kidney cancer and 50 healthy volunteers was undertaken using high-resolution proton nuclear magnetic resonance spectroscopy (H NMR) and silver-109 nanoparticle enhanced steel target laser desorption/ionization mass spectrometry (AgNPET LDI MS). Twelve potential urine biomarkers of kidney cancer were identified and quantified using one-dimensional (1D) H NMR metabolomics. Seven mass spectral features which differed significantly in abundance (p < 0.05) between kidney cancer patients and healthy volunteers were also detected using AgNPET-based laser desorption/ionization mass spectrometry (LDI MS). This work provides a framework to expand biomarker discovery that could be used as useful diagnostic or prognostic of kidney cancer progression.
肾癌是世界上泌尿系统最常见的癌症之一。尽管在肾癌治疗方面取得了重大进展，但目前尚无用于指导治疗干预的尿液特异性生物标志物。为了弥补这一知识空白，我们使用高分辨率质子核磁共振波谱（1H NMR）和银-109 纳米颗粒增强钢靶激光解吸/电离质谱（AgNPET LDI MS）对 50 例肾癌患者和 50 例健康志愿者的尿液样本进行了代谢组学分析。使用一维（1D）1H NMR 代谢组学方法鉴定和定量了 12 种潜在的肾癌尿液生物标志物。还使用基于 AgNPET 的激光解吸/电离质谱（LDI MS）检测到了在肾癌患者和健康志愿者之间丰度差异显著（p < 0.05）的 7 个质谱特征。这项工作为扩展生物标志物发现提供了一个框架，可用于肾癌的诊断或预后。
